Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab in Chinese patients with CNV secondary to AMD (EXTEND II)
NCT00826371Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2009
- Primary completion
- Jul 2010
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in choroidal neovascularization (CNV), age-related macular degeneration (AMD), sponsored by Novartis. Started Jan 2009; status: completed.
02
Drugs
ranibizumab
03
Conditions
choroidal neovascularization (CNV)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT00826371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00826371.